Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-630 adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma
2018-001974-76Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous squamous cell carcinoma (cSCC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Dec 2018; status: active.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2018-001974-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001974-76.